19 - 24 March 2016
These are links to news stories from the last week that may be of interest to people in the UK. The link beneath each item will take you to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter or regular email alerts.
World Congress on Controversies in Neurology (CONy)
A meeting that took place in Lisbon from 17-20 March. Presentations included a number of debates on research topics
A debate as to whether vitamin D can be considered disease modifying.
MRI and disease modifying drugs
A debate around the role of MRI in managing disease modifying drugs in relapsing remitting MS
Disease modifying drugs and biomarkers
Study looking at biomarkers in the blood to who would benefit from treatment with beta interferon
Disease modifying drugs for secondary progressive MS
A debate about the value of disease modifying drugs once someone no longer has relapsing remitting MS
A debate on the value of remyelination treatments and whether promoting remyelination is proven to have long-term benefits
B vs T cells
A debate about whether to target T cells as well as B cells in treating MS.
The pros and cons of treatments known to raise the risk of PML
Proposed benefit changes withdrawn
Ibudilast fast track status
The company developing ibudilast as a potential treatment for progressive MS has announced that it will be classed as a "Fast Track Product" by the FDA, the US drug regulator. This means quicker appraisal when the drug is submitted for licensing after phase III trials. Ibudilast is currently being tested in a phase II trial that is due to complete in 2017.
Source: National MS Society
MS Trust link: Ibudilast